{"id":1443,"date":"2010-02-23T16:09:16","date_gmt":"2010-02-23T21:09:16","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/tuesday-february-23-news-roundup-avandia-remains-in-the-news-dutch-study-questions-platelet-function-tests-iom-report-on-hypertension\/"},"modified":"2011-07-19T17:45:02","modified_gmt":"2011-07-19T21:45:02","slug":"tuesday-february-23-news-roundup-avandia-remains-in-the-news-dutch-study-questions-platelet-function-tests-iom-report-on-hypertension","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/02\/23\/tuesday-february-23-news-roundup-avandia-remains-in-the-news-dutch-study-questions-platelet-function-tests-iom-report-on-hypertension\/","title":{"rendered":"Tuesday, February 23 News Roundup: Avandia Remains in the News; Dutch Study Questions Platelet Function Tests; IOM Report on Hypertension"},"content":{"rendered":"<p><strong>Avandia Stays in the News:<\/strong> Responding to <a href=\"http:\/\/cardioexchange.org\/blogPost?postId=459\">all the news last weekend about rosiglitazone (Avandia<\/a>), the FDA announced\u00a0<a href=\"http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm201446.htm\">an ongoing review of the cardiovascular safety of Avandia<\/a> based on the RECORD trial\u00a0and published\u00a0<a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm201418.htm\">a safety announcement along with additional information for patients and healthcare professionals.<\/a> Adding even more drama to events,\u00a0<a href=\"http:\/\/www.nytimes.com\/2010\/02\/23\/health\/23niss.html\">a <\/a><a href=\"http:\/\/www.nytimes.com\/2010\/02\/23\/health\/23niss.html\"><em>New York Times<\/em> s<\/a><a href=\"http:\/\/www.nytimes.com\/2010\/02\/23\/health\/23niss.html\">tory by\u00a0Gardiner Harris<\/a><a href=\"http:\/\/www.nytimes.com\/2010\/02\/23\/health\/23niss.html\"> <\/a>tells how Cleveland Clinic cardiologist Steve Nissen\u00a0secretly recorded a meeting with GlaxoSmithKline executives in 2007, immediately prior to the publication o<a href=\"http:\/\/search.nejm.org\/search?p=R&amp;srid=S9%2d4&amp;lbc=nejm&amp;w=nissen%20wolski&amp;url=http%3a%2f%2fcontent%2enejm%2eorg%2fcgi%2fcontent%2fshort%2f356%2f24%2f2457&amp;rk=1&amp;uid=952727838&amp;sid=2&amp;ts=subs&amp;rsc=tNGCvP:5DtB3NiUo&amp;method=and&amp;isort=score&amp;start%5fyear=2000&amp;start%5fmonth=2&amp;rurl=yes&amp;nurl=http%3a%2f%2fcontent%2enejm%2eorg%2fcgi%2fcontent%2ffull%2f356%2f24%2f2457\">f the <em>NEJM<\/em> meta-analysis<\/a> that started the Avandia controversy.<\/p>\n<p><strong>Dutch Study Questions Platelet Function Tests:<\/strong> A <a href=\"http:\/\/jama.ama-assn.org\/cgi\/content\/short\/303\/8\/754\">study in <em>JAMA<\/em> <\/a>from the Netherlands compared six platelet function tests in low-risk patients undergoing elective PCI. Three of the tests\u00a0\u2014 light transmittance aggregometry, VerifyNow, and Plateletworks\u00a0\u2014 were found to have &#8220;a modest ability&#8221; to predict outcomes. The authors say the study\u00a0&#8220;does not support the use of platelet function testing to guide clinical practice in a low-risk population of patients undergoing elective PCI.&#8221;<\/p>\n<p><strong>IOM Report on Hypertension:<\/strong> The Institute of Medicine released <a href=\"http:\/\/www.iom.edu\/Reports\/2010\/A-Population-Based-Policy-and-Systems-Change-Approach-to-Prevent-and-Control-Hypertension\/Report-Brief-Prevent-and-Control-Hypertension.aspx\">a report on hypertension<\/a>. Noting that nearly one-third of American adults have high blood pressure, the report calls for population-based strategies to reduce the incidence of this\u00a0<a href=\"http:\/\/www8.nationalacademies.org\/onpinews\/newsitem.aspx?RecordID=12819\">&#8220;neglected disease,&#8221;<\/a> and says medical professionals need to do a better job in diagnosing and treating patients with hypertension.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avandia Stays in the News: Responding to all the news last weekend about rosiglitazone (Avandia), the FDA announced\u00a0an ongoing review of the cardiovascular safety of Avandia based on the RECORD trial\u00a0and published\u00a0a safety announcement along with additional information for patients and healthcare professionals. Adding even more drama to events,\u00a0a New York Times story by\u00a0Gardiner Harris [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1443","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1443"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1443\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}